Apellis Pharma Secures FDA Approval For EMPAVELI To Treat Rare Kidney Disorders

Source: NASDAQ Markets | Published: July 29, 2025, 4:03 am | Read Original

Strong Bullish 100.0

(RTTNews) - Apellis Pharmaceuticals Inc. (APLS) announced that the U.S. Food and Drug Administration has approved EMPAVELI (pegcetacoplan) as the first treatment for C3 glomerulopathy (C3G) or primary immune complex membranoproliferative glomerulonephritis (IC-MPGN) in patients 1

Read Source Login to use Pulse AI

Pulse AI Analysis

Pulse analysis not available yet. Click "Get Pulse" above.

This analysis was generated using Pulse AI, Glideslope's proprietary AI engine designed to interpret market sentiment and economic signals. Results are for informational purposes only and do not constitute financial advice.

More Like This

Glideslope AI

Apellis Pharma Secures FDA Approval For EMPAVELI To Treat Rare Kidney Disorders

(RTTNews) - Apellis Pharmaceuticals Inc. (APLS) announced that the U.S. Food and Drug Administration has approved EMPAVELI (pegcetacoplan) as the first treatment for C3 glomerulopathy (C3G) or primary immune complex membranoproliferative glomerulonephritis (IC-MPGN) in patients 1

NASDAQ Markets • Jul 29, 2025 • Found on Glideslope.ai

Post hash: 24394804245117646136 • glideslope.ai/post/24394804245117646136

Sentiment

Strong Bullish • Score: 100.0

-100 (Bearish) +100 (Bullish)

Fraywire Market Portal, Breaking Metrics Newsletter, and Glideslope AI are designed for informational purposes only. The content provided across these platforms—including, but not limited to, stock and crypto watchlists, price tracking, trade tracking, sentiment analysis, and news articles—should not be construed as financial advice or research reports. Users are encouraged to conduct their own research and consult with qualified financial professionals before making any investment decisions. While we strive to ensure the accuracy, completeness, and reliability of the information provided, Fraywire, Breaking Metrics, and Glideslope AI make no guarantees or warranties regarding the content's validity. By using these platforms, you acknowledge and agree that you are solely responsible for your own investment decisions and actions. Fraywire, Breaking Metrics, and Glideslope AI shall not be held liable for any losses or damages resulting from the use of the information provided.

Get Connected

Fraywire & Glideslope AI are Breaking Metrics productions.
Contact the developer for advertising opportunities, questions, and more at roy@rmahd.com

○ Subscribe
○ Fraywire+
○ Glideslope AI
○ Blog
○ RMAHD
○ Merch!

" selected code.

Pulse AI Analysis

Related Insights

More Like This

Approval of Bad Bunny Super Bowl show split along partisan lines, poll finds

Is Union Pacific Trump ballroom donation Vena’s merger knockout punch?

Novartis is in talks to buy U.S. biotech firm Avidity Biosciences for more than $70 a share, Bloomberg News reports

Over 140,000 bottles of popular cholesterol drug Atorvastatin recalled by FDA

How direct-to-patient deliveries are shaping pharma

Resignation, shock, approval: A mix of emotions as East Wing demolished